ArticleJournal of nephrology2019
Increased but stable isoagglutinin titers in hemodialysis patients.
Article in Journal of nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 7 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrior to an ABO incompatible kidney transplantation it is important to know the recipient's pre-transplantation anti-A and/or anti-B (isoagglutinin) titer. This study determined if pre-transplantation isoagglutinin titers remained stable, over a period of 1 year, among hemodialysis patients.
methodBlood was collected four times, every 3 months from 54 hemodialysis patients (hemodialysed trice per week ≥ 6 months), and 56 healthy volunteers. Measurement of anti-A and anti-B (IgM and IgG) titers were performed on an automated solid phase analyzer. The titers were converted to log
resultsWithin blood group O, mean IgG anti-A and anti-B titers were significantly higher in the hemodialysis patients (n = 22, mean titer step: anti-A: 6.4 and anti-B:4.9), compared to the healthy volunteers [n = 19, mean titer step: anti-A: 4.9 and anti-B:3.5, p = 0.02 (anti-A) and p = 0.03 (anti-B)], despite blood group O hemodialysis patients having significantly lower total plasma IgG levels (median 8.1 g/L) than healthy volunteers (11.1 g/L, p = 0.001). Neither age, nor gender determined IgG anti-A or anti-B titers. In hemodialysis patients and healthy volunteers, the upper 95% confidence limit of anti-A and anti-B titer variation (IgM and IgG) during 1 year, did not exceed 1.0 titer step in any of the ABO groups.
conclusionsAnti-A and -B titers (IgM and IgG) remained stable in both the hemodialysis patients and healthy volunteers over a period of approximately 1 year. Blood group O hemodialysis patients had, despite lower total IgG levels, significantly elevated IgG anti-A and -B titers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.